Health
Xinhua Silk Road: Italy-based Salov, subsidiary of China's Bright Food Group, promotes olive oil culture through talent dev't programs
BEIJING, Aug. 15, 2024 /PRNewswire/ -- Salov SpA (Salov), an Italy-based edible oil producer that owns the globally recognized olive oil brands Filippo Berio and Sagra and was acquired byChina's Bright Food Group in 2015, has been advancing olive oil culture through talent development programs. ...
2024-08-15 15:54
1576
Ivonescimab (PD-1/VEGF) Received Priority Review from China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC
The Second Indication of Ivonescimab in NSCLC 2L+ EGFRm NSCLC Already Approved in May 2024 HONG KONG, Aug. 14, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced that the National Center for Drug Evaluation of the State Drug Administration ofthe People's Republic of China...
2024-08-15 07:30
1634
Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"
CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: QLI), aChina-based pharmaceutical and chemical products manufacturer, announced today that effective onAugust 11, 2024, its Class A ordinary shares will begin trading on the...
2024-08-13 20:00
2626
Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program
* Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. onJuly 2, 2023 * Adalimumab-aaty's inclusion creates greater accessibility to treatments for Americans with inflammatory conditions...
2024-08-13 07:46
1515
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been granted Breakthrough Therapy Designation (BTD) bythe Center for Drug Evaluation (CDE) of China's...
2024-08-12 22:00
1843
Momcozy's Ongoing Campaign for Breastfeeding Awareness Month Connects Moms and Breaks Barriers
NEW YORK, Aug. 12, 2024 /PRNewswire/ -- During Breastfeeding Awareness Month,
global mother and baby brandMomcozy
2024-08-12 22:00
1126
Xiao-I Corporation Showcases Hearview Smart Glasses at Successful U.S. Launch Event
SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- Xiao-I Corporation ("Xiao-I" or the "Company") (NASDAQ: AIXI), a leading artificial intelligence company, is proud to announce the successful U.S. launch of its innovative Hearview Smart Glasses. The event, which was streamed live on YouTube onAugust 8th at...
2024-08-12 21:30
2770
VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism
* 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primarymulti-component endpoint compared to 0.0% for placebo (p <0.0001) * Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug. SHANGHAI, Aug. 12...
2024-08-12 21:00
1753
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.[1] The primary endpoint of superiority to placebo in a cognitive "attention composite" of three Cogstate computerized tests was not met with large improvements seen in both Xan...
2024-08-12 20:30
1762
Milestone: Renal Nerve Mapping / Selective Renal Denervation (msRDN) System by SyMap Medical Ltd Approved for Treatment of Uncontrolled Hypertension in China
SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- On August 6, 2024, the msRDN System (SyMapCath I®/ SYMPIONEER S1®), developed by Suzhou/China-based SyMap Medical Ltd. (SyMap Medical), was approved by the National Medical Products Administration (NMPA) ofChina and granted a Class III Medical Devices ...
2024-08-12 13:55
1300
IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Two New Autoimmune Disease Indications
SHANGHAI, NANJING, China and SAN JOSE, Calif., Aug. 12, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced that the investigation...
2024-08-12 13:52
1343
The San Ignacio Hospital project in Peru was officially handed over
BEIJING, Aug. 11, 2024 /PRNewswire/ -- On 1 August local time, the San Ignacio Hospital project inPeru, constructed by POWERCHINA, successfully passed the final acceptance of the owner and obtained the official handover certificate. This project is the first hospital project formally handed over ...
2024-08-12 10:55
2319
GenScript Biotech Reports First Half 2024 Results
Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development * Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing s...
2024-08-09 23:19
3645
Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo
VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly integrate the functionality of a smartwatch with that of an anti-nausea wristband, ensuring a carefree and healthy life for all. EmeTerm® Smart is launching on Indiegogo as the world's first a...
2024-08-08 23:00
1452
T-MAXIMUM PHARMACEUTICAL Announces Latest Clinical Advances in Allogeneic CAR-T Cell Therapy Breakthrough for Solid Tumors
Summary * T-Maximum Pharmaceutical develops allogeneic CAR-T therapies with a unique CRISPR/Cas9 Gene-Editing platform for solid tumors, provide a solution of two major pain points, GvHD and HvG, aiming to revolutionize cancer. * MT027, the product of target B7H3 received US FDA orphan drug d...
2024-08-08 20:00
2095
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
* Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ * Collaboration is a three-year and potentially multi-TCR p...
2024-08-08 16:00
1680
WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine
CHENGDU, China, Aug. 7, 2024 /PRNewswire/ -- WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals fromChina's National Medical Products Administration (NMPA) and the US FDA. This unprecedented achievement marks the world's firs...
2024-08-08 10:59
1481
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
BEIJING, Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it has received a letter from the New York Stoc...
2024-08-07 20:30
3163
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States
TAIPEI, Aug. 7, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has signed a non-binding terms agreement with Eyenovia, Inc. ("Eyenovia", NASDAQ: EYEN), whereby the companies will co-develop Clobetasol Propionate Ophthalmic Suspensi...
2024-08-07 20:00
2006
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) ("I-Mab", the "Company"), a U.S.-based, global biotech company, exclusively f...
2024-08-07 19:00
1222
Week's Top Stories
Most Reposted
Thailand Tops 2024 Consumer Review Awards by Agoda
[Picked up by 329 media titles]
2024-09-26 11:00
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
[Picked up by 314 media titles]
2024-09-26 00:00
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
[Picked up by 312 media titles]
2024-09-23 13:37
Circles Partners with Telkomsel, Providing an Advanced Software-as-a-Service (SaaS) Platform to Enhance Customer Digital Experience
[Picked up by 297 media titles]
2024-09-27 10:00RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
[Picked up by 294 media titles]
2024-09-23 22:00
Most Read
RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
2024-09-23 22:00
6924
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
2024-09-23 13:37
6305
